RBC Capital on Jazz Pharmaceuticals (JAZZ): 'we would be buyers on the potential upcoming positive ph.III zanidatimab data in GEA'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $151.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
